Best Practices and Research Advances in Thoracic Oncology: A Regional Series Eastern Europe/Baltic Course 2: Immunotherapy in Lung Cancer-Adjuvant Treatment: A New Opportunity

Video Transcription

Video Summary

Dr. Rafał Dziadziuszko, a thoracic oncologist, discusses the adjuvant treatment standards for operable non-small cell lung cancer (NSCLC). Surgery is the primary treatment for stages 1 to 3a NSCLC, complemented by systemic therapies for advanced stages. Segmentectomy is preferred over lobectomy, minimizing pulmonary function loss. Adjuvant chemotherapy, used for 20 years, reduces death risk modestly but is not beneficial for all stages. Targeted therapies, such as osimertinib and alectinib, show significant benefits for patients with specific mutations like EGFR and ALK. In adjuvant immunotherapy trials, agents like pembrolizumab and atezolizumab demonstrate disease-free survival benefits in specific contexts. Neoadjuvant chemoimmunotherapy provides consistent survival benefits, prompting questions about the necessity and duration of adjuvant treatments. Tailored treatment strategies based on individual patient characteristics, including molecular markers and PD-L1 expression, are crucial. Multidisciplinary care enhances treatment outcomes for NSCLC patients.

Asset Subtitle

Rafal Dziadziuszko, MD, PhD

Keywords

NSCLC

adjuvant therapy

targeted therapies

immunotherapy

molecular markers

multidisciplinary care